bioAffinity Technologies, Inc. (BIAF)
Develops blood tests that detect lung cancer early using flow cytometry analysis.
$0.62-0.09%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-92.9%
The outlook
BIAF trades near its 52-week low, sitting well below both its 50- and 200-day moving averages. Analyst coverage appears sparse or unavailable. The overall sentiment leans heavily bearish based on current price positioning and trend weakness.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range0% of the way from its 52-week low to high
Market cap
$3.9M
52-wk high
$13.50
52-wk low
$0.60
50-day avg
$1.17
200-day avg
$1.76
Trailing P/E
—